Literature DB >> 19717648

C/EBPbeta regulates transcription factors critical for proliferation and survival of multiple myeloma cells.

Rekha Pal1, Martin Janz, Deborah L Galson, Margarete Gries, Shirong Li, Korinna Jöhrens, Ioannis Anagnostopoulos, Bernd Dörken, Markus Y Mapara, Lisa Borghesi, Lela Kardava, G David Roodman, Christine Milcarek, Suzanne Lentzsch.   

Abstract

CCAAT/enhancer-binding protein beta (C/EBPbeta), also known as nuclear factor-interleukin-6 (NF-IL6), is a transcription factor that plays an important role in the regulation of growth and differentiation of myeloid and lymphoid cells. Mice deficient in C/EBPbeta show impaired generation of B lymphocytes. We show that C/EBPbeta regulates transcription factors critical for proliferation and survival in multiple myeloma. Multiple myeloma cell lines and primary multiple myeloma cells strongly expressed C/EBPbeta, whereas normal B cells and plasma cells had little or no detectable levels of C/EBPbeta. Silencing of C/EBPbeta led to down-regulation of transcription factors such as IRF4, XBP1, and BLIMP1 accompanied by a strong inhibition of proliferation. Further, silencing of C/EBPbeta led to a complete down-regulation of antiapoptotic B-cell lymphoma 2 (BCL2) expression. In chromatin immunoprecipitation assays, C/EBPbeta directly bound to the promoter region of IRF4, BLIMP1, and BCL2. Our data indicate that C/EBPbeta is involved in the regulatory network of transcription factors that are critical for plasma cell differentiation and survival. Targeting C/EBPbeta may provide a novel therapeutic strategy in the treatment of multiple myeloma.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19717648      PMCID: PMC2773489          DOI: 10.1182/blood-2009-01-201111

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  46 in total

1.  Plasma cell differentiation requires the transcription factor XBP-1.

Authors:  A M Reimold; N N Iwakoshi; J Manis; P Vallabhajosyula; E Szomolanyi-Tsuda; E M Gravallese; D Friend; M J Grusby; F Alt; L H Glimcher
Journal:  Nature       Date:  2001-07-19       Impact factor: 49.962

2.  Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and BCL2A1 as critical target genes.

Authors:  Roberto Piva; Elisa Pellegrino; Michela Mattioli; Luca Agnelli; Luigia Lombardi; Francesco Boccalatte; Giulia Costa; Bruce A Ruggeri; Mangeng Cheng; Roberto Chiarle; Giorgio Palestro; Antonino Neri; Giorgio Inghirami
Journal:  J Clin Invest       Date:  2006-11-16       Impact factor: 14.808

Review 3.  Regulation of plasma-cell development.

Authors:  Miriam Shapiro-Shelef; Kathryn Calame
Journal:  Nat Rev Immunol       Date:  2005-03       Impact factor: 53.106

4.  Enzastaurin (LY317615), a protein kinase Cbeta inhibitor, inhibits the AKT pathway and induces apoptosis in multiple myeloma cell lines.

Authors:  Mujahid A Rizvi; Kulsoom Ghias; Katharine M Davies; Chunguang Ma; Frank Weinberg; Hidayatullah G Munshi; Nancy L Krett; Steven T Rosen
Journal:  Mol Cancer Ther       Date:  2006-07       Impact factor: 6.261

5.  CCAAT/enhancer binding protein epsilon is critical for effective neutrophil-mediated response to inflammatory challenge.

Authors:  J Lekstrom-Himes; K G Xanthopoulos
Journal:  Blood       Date:  1999-05-01       Impact factor: 22.113

6.  CCAAT-enhancer-binding protein beta (C/EBP beta) activates CCR5 promoter: increased C/EBP beta and CCR5 in T lymphocytes from HIV-1-infected individuals.

Authors:  M Rosati; A Valentin; D J Patenaude; G N Pavlakis
Journal:  J Immunol       Date:  2001-08-01       Impact factor: 5.422

7.  A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6.

Authors:  Linda B Baughn; Maurizio Di Liberto; Kaida Wu; Peter L Toogood; Tracey Louie; Rachel Gottschalk; Ruben Niesvizky; Hearn Cho; Scott Ely; Malcolm A S Moore; Selina Chen-Kiang
Journal:  Cancer Res       Date:  2006-08-01       Impact factor: 12.701

8.  IL-21 induces differentiation of human naive and memory B cells into antibody-secreting plasma cells.

Authors:  Rachel Ettinger; Gary P Sims; Anna-Marie Fairhurst; Rachel Robbins; Yong Sing da Silva; Rosanne Spolski; Warren J Leonard; Peter E Lipsky
Journal:  J Immunol       Date:  2005-12-15       Impact factor: 5.422

9.  Transcription factor IRF4 controls plasma cell differentiation and class-switch recombination.

Authors:  Ulf Klein; Stefano Casola; Giorgio Cattoretti; Qiong Shen; Marie Lia; Tongwei Mo; Thomas Ludwig; Klaus Rajewsky; Riccardo Dalla-Favera
Journal:  Nat Immunol       Date:  2006-06-11       Impact factor: 25.606

10.  NPM-ALK-dependent expression of the transcription factor CCAAT/enhancer binding protein beta in ALK-positive anaplastic large cell lymphoma.

Authors:  Leticia Quintanilla-Martinez; Stefania Pittaluga; Cornelius Miething; Margit Klier; Martina Rudelius; Theresa Davies-Hill; Natasa Anastasov; Antonio Martinez; Angelica Vivero; Justus Duyster; Elaine S Jaffe; Falko Fend; Mark Raffeld
Journal:  Blood       Date:  2006-05-18       Impact factor: 22.113

View more
  34 in total

1.  RNA interference screening identifies lenalidomide sensitizers in multiple myeloma, including RSK2.

Authors:  Yuan Xiao Zhu; Hongwei Yin; Laura A Bruins; Chang-Xin Shi; Patrick Jedlowski; Meraj Aziz; Chris Sereduk; Klaus Martin Kortuem; Jessica E Schmidt; Mia Champion; Esteban Braggio; A Keith Stewart
Journal:  Blood       Date:  2014-11-13       Impact factor: 22.113

2.  An isoform-specific C/EBPβ inhibitor targets acute myeloid leukemia cells.

Authors:  A Jakobs; S Uttarkar; C Schomburg; S Steinmann; A Coulibaly; P Schlenke; W E Berdel; C Müller-Tidow; T J Schmidt; K-H Klempnauer
Journal:  Leukemia       Date:  2016-02-08       Impact factor: 11.528

3.  Loss of FAM46C Promotes Cell Survival in Myeloma.

Authors:  Yuan Xiao Zhu; Chang-Xin Shi; Laura A Bruins; Patrick Jedlowski; Xuewei Wang; K Martin Kortüm; Moulun Luo; Jonathan M Ahmann; Esteban Braggio; A Keith Stewart
Journal:  Cancer Res       Date:  2017-06-15       Impact factor: 12.701

4.  C/EBPα, C/EBPα oncoproteins, or C/EBPβ preferentially bind NF-κB p50 compared with p65, focusing therapeutic targeting on the C/EBP:p50 interaction.

Authors:  Julia E Dooher; Ido Paz-Priel; Simone Houng; Albert S Baldwin; Alan D Friedman
Journal:  Mol Cancer Res       Date:  2011-08-03       Impact factor: 5.852

5.  Tumor necrosis factor α- and interleukin-1β-dependent induction of CCL3 expression by nucleus pulposus cells promotes macrophage migration through CCR1.

Authors:  Jianru Wang; Ye Tian; Kate L E Phillips; Neil Chiverton; Gail Haddock; Rowena A Bunning; Alison K Cross; Irving M Shapiro; Christine L Le Maitre; Makarand V Risbud
Journal:  Arthritis Rheum       Date:  2013-03

6.  Altered PKR Signalling and C / EBPβ Expression is Associated with HLA-B27 Expression in Monocytic Cells.

Authors:  A S Sahlberg; M Ruuska; R A Colbert; K Granfors; M A Penttinen
Journal:  Scand J Immunol       Date:  2012-02       Impact factor: 3.487

7.  The CCAAT/enhancer-binding protein beta-2 isoform (CEBPβ-2) upregulates galectin-7 expression in human breast cancer cells.

Authors:  Carole G Campion; Marilyne Labrie; Andrée-Anne Grosset; Yves St-Pierre
Journal:  PLoS One       Date:  2014-05-02       Impact factor: 3.240

8.  Bortezomib induction of C/EBPβ mediates Epstein-Barr virus lytic activation in Burkitt lymphoma.

Authors:  Courtney M Shirley; Jianmeng Chen; Meir Shamay; Huili Li; Cynthia A Zahnow; S Diane Hayward; Richard F Ambinder
Journal:  Blood       Date:  2011-03-29       Impact factor: 22.113

9.  Cigarette smoke induces C/EBP-β-mediated activation of miR-31 in normal human respiratory epithelia and lung cancer cells.

Authors:  Sichuan Xi; Maocheng Yang; Yongguang Tao; Hong Xu; Jigui Shan; Suzanne Inchauste; Mary Zhang; Leandro Mercedes; Julie A Hong; Mahadev Rao; David S Schrump
Journal:  PLoS One       Date:  2010-10-29       Impact factor: 3.240

10.  Zinc Finger Homeodomain Factor Zfhx3 Is Essential for Mammary Lactogenic Differentiation by Maintaining Prolactin Signaling Activity.

Authors:  Dan Zhao; Gui Ma; Xiaolin Zhang; Yuan He; Mei Li; Xueying Han; Liya Fu; Xue-Yuan Dong; Tamas Nagy; Qiang Zhao; Li Fu; Jin-Tang Dong
Journal:  J Biol Chem       Date:  2016-04-20       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.